The introduction of cancer immunotherapies, including those targeting CTLA-4 and programed cell death 1 (PD-1)/PD-L1, has highlighted the therapeutic relevance of understanding the regulation of local tumor immunity (18, 19). Here, PDCD1 is linked to cancer.